Sigilon Therapeutics Inc (SGTX)

NASDAQ
5.81
-0.04(-0.68%)
Pre Market
5.93
+0.12(+2.07%)
- Real-time Data
  • Volume:
    37,645
  • Bid/Ask:
    5.61/6.65
  • Day's Range:
    5.62 - 5.88

SGTX Overview

Prev. Close
5.85
Day's Range
5.62-5.88
Revenue
13.62M
Open
5.79
52 wk Range
4.33-54.32
EPS
-2.12
Volume
37,645
Market Cap
186.25M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
180,048
P/E Ratio
-
Beta
-
1-Year Change
-
Shares Outstanding
32,057,253
Next Earnings Date
Dec 01, 2021
What is your sentiment on Sigilon Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

Sigilon Therapeutics Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyStrong BuyBuySell
Technical IndicatorsStrong SellStrong BuyStrong BuyStrong BuySell
SummaryNeutralStrong BuyStrong BuyStrong BuySell

Sigilon Therapeutics Inc Company Profile

Sigilon Therapeutics Inc Company Profile

Sector
Services
Employees
99

Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Read More
  • To where
    0
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.